The Journal‪.‬ The Wall Street Journal

The billionaire founder showed several female employees at SpaceX an unusual amount of attention or pursued them. WSJ's Joseph Palazzolo describes the revelations.



Further Reading:

-Elon Musk’s Boundary-Blurring Relationships With Women at SpaceX 



Further Listening:

-Money, Drugs, Elon Musk and Tesla's Board 

-Elon Musk's 'Demon Mode' 

Learn more about your ad choices. Visit megaphone.fm/adchoices

The nation’s first congestion-pricing plan was set to take effect at the end of June. But last week, New York Gov. Kathy Hochul called to indefinitely delay the program. WSJ's Jimmy Vielkind unpacks the surprising move and explores why Hochul made the 11th hour change.



Further Reading:

-New York Gov. Kathy Hochul Abruptly Halts Manhattan Congestion Pricing 



Further Listening:

-NYC’s Food Delivery Workers Fight for a Minimum Wage 

-New York City's 'De Facto Ban' on Airbnb 

Learn more about your ad choices. Visit megaphone.fm/adchoices

The fast-fashion giant hoped to have a splashy U.S. public offering this year. WSJ's Shen Lu explains how the divide between Beijing and Washington got in the way.



Further Reading:

- Shein Promised to Have a Big U.S. IPO. Its China Roots Got in the Way. 

- Fast-Fashion Giant Shein Files to Go Public 



Further Listening:

- Shein Took Over Fast Fashion. Then Came the Backlash. 

- The Mysterious CEO Leading Shein to an IPO 



Learn more about your ad choices. Visit megaphone.fm/adchoices

The rising popularity of GLP-1 drugs could cause all kinds of ripple effects.

According to one estimate, 9% of the U.S. population could be on Ozempic or similar medications by 2030. Meanwhile, drugmakers are already developing the next generation of weight-loss drugs and researchers are studying the possible health benefits beyond weight loss and diabetes, including addiction.

In the final episode of our series we ask: What could all this development mean for businesses, from the food sector to airlines? And who wins and who loses in the post-Ozempic economy?

Guests include: David Ricks, CEO of Eli Lilly; and Mehdi Farokhnia, an addiction researcher at the National Institutes of Health.

Listen to Episodes 1, 2 and 3 of “Trillion Dollar Shot” here. 
Learn more about your ad choices. Visit megaphone.fm/adchoices

There is a new contender in the cola wars, and it isn’t a cola. It’s Dr Pepper. WSJ’s Jennifer Maloney unpacks how after decades as a distant competitor, Dr Pepper has climbed the soda ranks with help from hefty marketing, novel flavors and TikTok videos.



Further Reading:

- Dr Pepper Ties Pepsi as America’s No. 2 Soda



Further Listening:

- The Agony and Ecstasy of Tab 



Learn more about your ad choices. Visit megaphone.fm/adchoices

President Biden unveiled a last-ditch effort to lower illegal crossings at the southern border this week. The move focuses on asylum seekers, and the policy is similar to one that former President Trump tried in 2018. WSJ’s Michelle Hackman describes the policy and tries to answer the question: why now?



Further Reading:

-Biden Issues Executive Actions on Immigration: What to Know 





Further Listening:

-What the End of Title 42 Means for U.S. Immigration Policy 

-What Trump's Immigration Restrictions Could Mean for the Economy 

Learn more about your ad choices. Visit megaphone.fm/adchoices